Accenture insider trading
Every open-market purchase and sale by Accenture's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Accenture’s insiders pay?
From January 4, 2010 to October 22, 2026, 31 insiders reported 1 open-market purchase and 76 sales not made under a pre-set plan in Accenture. Twelve months after each purchase was reported, the shares were −10.3% against the S&P 500 on average (median −10.3%), over 1 purchase with a full year of prices; 0% beat the index. After sales, the shares moved +4.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on July 3, 2013 into $14,875 by November 2, 2026, +3.0% a year. It held shares 8% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $16,200 (+3.7% a year), and held throughout $58,638 (+14.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Casati Gianfranco | Group Chief Executive-Products | 0 | — | — | 7 | +10.0% (7) | April 3, 2012 |
| Lumb Richard | Group Chief Executive-Fin Serv | 0 | — | — | 7 | −10.4% (7) | July 17, 2013 |
| Foster Mark | Grp Chief Exec-Mgmt Consulting | 0 | — | — | 6 | +11.3% (6) | February 8, 2011 |
| Kimsey William L | Director | 0 | — | — | 5 | +4.6% (5) | May 1, 2013 |
| Price Paula A | Director | 0 | — | — | 5 | −4.1% (5) | December 26, 2023 |
| Dublon Dina | Director | 0 | — | — | 4 | +5.5% (4) | April 9, 2013 |
| Mcgarvie Blythe J | Director | 0 | — | — | 4 | +6.7% (4) | October 3, 2014 |
| Sell Robert E | Grp Chief Exec-Com, Med & Tech | 0 | — | — | 4 | +3.9% (4) | October 4, 2016 |
| Frerichs Robert N | Group Chief Exec-North America | 0 | — | — | 3 | +19.0% (3) | February 14, 2011 |
| Lipp Robert I | Director | 0 | — | — | 3 | +7.0% (3) | October 4, 2012 |
| Smart Jill | Chief Human Resources Officer | 0 | — | — | 3 | −4.2% (3) | December 26, 2013 |
| Van 't Noordende Alexander M | Group Chief Exec-Products | 0 | — | — | 3 | +23.6% (3) | July 1, 2015 |
| Clark Richard P | Chief Accounting Officer | 0 | — | — | 2 | +7.5% (2) | July 8, 2014 |
| Coughlan Anthony G | Principal Accounting Officer | 0 | — | — | 2 | +0.7% (2) | April 3, 2013 |
| Deblaere Johan | Chief Operating Officer | 0 | — | — | 2 | −1.4% (2) | April 12, 2013 |
| Moodystuart Mark | Director | 0 | — | — | 2 | +2.3% (2) | June 30, 2011 |
| Ardila Jaime | Director | 0 | — | — | 1 | −23.0% (1) | December 28, 2023 |
| Clifford Katherine Lee | Chief Leadership & HR Officer | 0 | — | — | 1 | — | August 17, 2026 |
| Hightower Dennis F | Director | 0 | — | — | 1 | +17.5% (1) | February 15, 2012 |
| Idei Nobuyuki | Director | 0 | — | — | 1 | +6.4% (1) | April 3, 2012 |
| London Daniel T | Grp Chief Exec-Health & PS | 0 | — | — | 1 | +17.0% (1) | July 7, 2014 |
| Magner Marjorie | Director | 0 | — | — | 1 | −11.9% (1) | April 11, 2016 |
| Nanterme Pierre | Chairman & CEO | 0 | — | — | 1 | +17.0% (1) | July 7, 2014 |
| Osborne Jeffrey D | Chief Performance Officer | 0 | — | — | 1 | +14.8% (1) | January 19, 2012 |
| Pelisson Gilles | Director | 0 | — | — | 1 | −8.3% (1) | May 14, 2024 |
| Renduchintala Venkata S M | Director | 0 | — | — | 1 | +15.5% (1) | September 30, 2020 |
| Rohleder Stephen J | Group Chief Exec-Health & PS | 1 | −10.3% (1) | 0% | 0 | — | July 2, 2013 |
| Sarin Arun | Director | 0 | — | — | 1 | +10.1% (1) | October 10, 2018 |
| Schimmelmann Wulf Von | Director | 0 | — | — | 1 | −12.5% (1) | April 1, 2016 |
| Sekido Ryoji | Co-CEO Asia Pacific | 0 | — | — | 1 | — | October 22, 2026 |
| Shook Ellyn | Chief Human Resources Officer | 0 | — | — | 1 | +15.9% (1) | July 2, 2014 |
When several insiders traded Accenture
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Accenture in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 7 selling crowds, −0.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| July 31, 2014 | 5 selling | −1.4% | +3.1% | +22.1% |
| December 31, 2013 | 3 selling | −5.4% | −8.0% | −2.0% |
| April 30, 2013 | 5 selling | −15.6% | −19.0% | −19.3% |
| October 31, 2012 | 3 selling | +1.7% | +3.7% | −15.4% |
| February 29, 2012 | 3 selling | +1.4% | −0.9% | +15.1% |
| October 29, 2010 | 3 selling | +5.9% | +14.8% | +30.2% |
| April 30, 2010 | 4 selling | −2.4% | +3.3% | +16.2% |